Johnson // Becker, PLLC Reports on Medical Literature that Confirms Association Between Elmiron and Vision Damage

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Johnson // Becker, PLLC Reports on Medical Literature that Confirms Association Between Elmiron and Vision Damage

Medical researchers continue to report on increasing evidence of the association between long term-use of Elmiron (pentosan polysulfate sodium) and damage to the retina.

PR Newswire

ST. PAUL, Minn., Feb. 23, 2021 /PRNewswire/ -- Johnson // Becker, PLLC is a nationwide plaintiff's law firm with experience representing injured men and women in lawsuits against pharmaceutical and medical device companies. Johnson // Becker represents several individuals who allege they have suffered permanent vision loss after use of the drug Elmiron

Recently, an article was published by Dr. Nieraj Jain from Emory University.  The article reports that a survey of over 900 respondents showed an adjusted odds ration of 2.41 for the highest exposed users to have a diagnosis of macular degeneration or pigmentary maculopathy.  This is consistent with other recent reports in the medical literature.  The article is Uner OE, Shah MK, and Jain N.  Pentosan Polysulfate and Vision: Finds from an International Survery of Exposed Individuals.  Retina. 2020 Dec 14, doi: 10.1097/IAE.0000000000003078.

Johnson & Johnson is a New Jersey Corporation.  Janssen Pharmaceuticals, part of the Johnson & Johnson umbrella of companies, is a Pennsylvania corporation.  These companies have marketed Elmiron since the 2000s. 

Johnson // Becker, PLLC filed the first Elmiron lawsuit in the country and has also filed an Elmiron class action lawsuit pertaining to medical monitoring. The Plaintiffs allege that the company has never provided any warning of maculopathy or retinopathy associated with use of the drug or warned patients to have regular eye exams to monitor vision while using the drug until the company updated the label in June, 2020.

Timothy J. Becker and Stacy K Hauer of Johnson // Becker are counsel of record. Mr. Becker and Ms. Hauer have a combined experience of more than 40 years of litigating mass tort cases involving pharmaceuticals and medical devices.

To learn more about Johnson // Becker's mass tort cases and Elmiron lawsuits, or to arrange a free, no obligation case review, visit or contact Johnson // Becker at (800) 279-6386.


Cision View original content to download multimedia:

SOURCE Johnson // Becker, PLLC

Copyright CNW Group 2021

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).